Loading
A phase 1/2 trial of Two IM injections Lenti-HPV-07 in cervical cancer and head and neck squamous cell carcinoma, run by Theravectys S.A., now recruiting.
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer is a phase 1/2 interventional study registered as NCT06319963 by Theravectys S.A., with 72 participants planned, started 2024-08-08 and due to reach its primary completion in 2026-06. Interventions recorded: Two IM injections Lenti-HPV-07 and One IM injection Lenti-HPV-07.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oropharyngeal cancer (tonsil and base of tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Cervical cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oropharyngeal cancer (tonsil and base of tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.